Private Placement Transactions:
Remix Therapeutics: The company raised $70 million of Series B venture funding from Alexandria Venture Investments, Foresite Capital Management and Atlas Venture on May 17, 2022, putting the company’s pre-money valuation at $150 million. The Column Group, ARCH Venture Partners, Casdin Capital and Surveyor Capital also participated in the round. The company is an operator of a biotechnology business intended to develop novel small molecule therapies designed to reprogram RNA processing and treat disease in new ways.
Cynosure: The company received $60 million of development capital from Clayton, Dubilier & Rice on May 17, 2022. The company is a developer and manufacturer of aesthetic treatment systems intended for the healthcare sector.
Locus Biosciences: The company raised $35 million of Series B venture funding from Tencent Holdings, Johnson & Johnson Innovation – JJDC and ARTIS Ventures on May 18, 2022, putting the company’s pre-money valuation at $195 million. Codon Capital, Viking Global Investors, Discovery Innovations and CARB-X also participated in the round. The company is a developer of a CRISPR-engineered precision antibacterial platform designed to revolutionize the treatment of bacterial disease.
Vyriad: The company raised $29.5 million of Series B venture funding in a deal led by Stine Seed Farm on May 17, 2022. Mayo Clinic Ventures, Regeneron Pharmaceuticals, Mirae Asset MAPS Investment, and Southeast Minnesota Capital Fund also participated in the round. The company is a clinical-stage business intended to help attack cancer cells, ignite immune responses, and prevent cancer recurrence.
Vivasure Medical: The company raised EUR 22 million of Series D venture funding from Evonik Venture Capital, Panakes Partners and Orchestra Medical Ventures on May 17, 2022. Fountain Healthcare Partners and EQT Life Sciences also participated in the round. The company is a developer of advanced polymer implants designed to focus on minimally invasive vessel closure.
Enumera Molecular: The company raised $16 million of Series A venture funding in a deal led by Arboretum Ventures on May 17, 2022, putting the company’s pre-money valuation at $6 million. The company is a developer of a biomolecule assessment platform designed to offer life science tools.
VitalTech: The company raised $14.1 million of Series 1 venture funding from undisclosed investors on May 18, 2022, putting the company’s pre-money valuation at $20 million. The company is a developer of a remote patient monitoring platform designed to help manage health, fitness and personal well-being.
Gilgamesh Pharmaceuticals: The company raised $13.8 million of venture funding from undisclosed investors on May 19, 2022. The company is a developer of central nervous system drugs intended to treat neurological disorders.
Deciphex: The company raised $11.5 million of Series B venture funding in a deal led by Act Venture Capital on May 19, 2022. Charles River Laboratories, Novartis, NextSteps Capital, Halo Business Angel Network, Irrus Investments and other undisclosed investors also participated in the round. The company is a developer of medical software applications designed for preclinical pathology.
Coya Therapeutics: The company raised $10.4 million of venture funding in the form of convertible debt from undisclosed investors on May 20, 2022. The company is an operator of a clinical-stage biotechnology company intended to develop approaches utilizing adaptive regulatory T cells to target disease.
Elasmogen: The company raised GBP 8 million of venture funding in a deal led by BGF and The Scottish National Investment Bank on May 18, 2022. Scottish Enterprise and other undisclosed investors also participated in the round. The company is a developer of novel therapies designed to treat inflammatory, autoimmune diseases and cancer.
Greater Good Health: The company raised $10 million of Series A venture funding in a deal led by LRVHealth on May 18, 2022. Optum Ventures, Martin Ventures, Health Velocity Capital and other undisclosed investors also participated in the round. The company is a developer of a tech-enabled digital healthcare platform designed to empower nurse practitioners and help them provide primary care to patients.
Inovus Medical: The company raised $7 million of venture funding from Norgine Ventures and other undisclosed investors on May 20, 2022. The company is a manufacturer of medical and surgical simulators intended to train surgical trainees or residents.
Infectious Disease Connect: The company raised $5.45 million of venture funding in the form of equity and convertible debt from undisclosed investors on May 19, 2022. The company is a provider of patient management services intended to deliver patient retention, patient transfer and other tertiary services.
LumaCyte: The company raised $4.3 million of venture funding in the form of convertible debt from undisclosed investors on May 17, 2022. The company is a developer of advanced research and bioanalytics technology designed to produce label-free, single-cell analysis and sorting instrumentation.
Polygon: The company raised $4.2 million of venture funding from undisclosed investors on May 20, 2022. The company is a provider of remote tele-assessment tests intended to provide clarity to students and families who are struggling with learning differences like dyslexia, ADHD, and autism.
Cardio Diagnostics: The company is in the process of raising venture funding on May 19, 2022. The company is a developer of medical kits designed for early detection and prevention of heart disease.
JoyBridge Kids: The company received an undisclosed amount of development capital from Frontline Healthcare Partners on May 16, 2022. The company is an operator of applied behavior analysis therapy clinics intended to provide supplemental services in speech and occupational therapy.
Nuvita: The company raised an undisclosed amount of venture funding from Saba Investments on May 18, 2022. The company is a provider of outcome-based science and technology services intended to promote employee engagement and wellbeing.
Sanderling Renal Services: The company received an undisclosed amount of development capital from Pharos Capital Group on May 16, 2022. The company is a provider of quality dialysis and nephrology services intended to connect high-quality medical facilities to communities around the world.
M&A Transactions:
Success TMS / Greenbrook TMS NeuroHealth Centers: The company, a subsidiary of Success Behavioral Holdings reached a definitive agreement to be acquired by Greenbrook TMS NeuroHealth Centersfor $27.3 million on May 16, 2022. The company is a provider of transcranial magnetic stimulation therapy services based in Palm Beach, United States.
Ketamine Health Centers / Irwin Naturals: The company was acquired by Irwin Naturals on May 20, 2022. The company is a provider of mental health and pain treatment services intended to provide relief from treatment-resistant conditions.
AffinityDNA / Genetic Technologies: The company reached a definitive agreement to be acquired by Genetic Technologies on May 16, 2022. The company is a provider of genetic testing services intended to offer fast, accurate, discreet, and accredited legal DNA tests at affordable prices.
3D Bio-Tissues / BSF Enterprise: The company was acquired by BSF Enterprise through a reverse merger on May 17, 2022. The company is a developer of bio-equivalent tissues intended for clinical and cellular agriculture.
Atrin Pharmaceuticals / Aprea Therapeutics: The company was acquired by Aprea Therapeutics for an undisclosed amount on May 16, 2022. The company is a developer of anticancer therapeutic drugs designed to treat a broad spectrum of cancers associated with synthetic lethality and the deregulated DNA damage response.
Bandera Family Medical Group / VillageMD: The company was acquired by VillageMD for an undisclosed amount on May 19, 2022. The company is an operator of a medical clinic intended to provide inpatient care services.
BSF Enterprise / 3D Bio-Tissues: The company was acquired by 3D Bio-Tissues through a reverse merger on May 17, 2022. BSF Enterprise PLC provides investment opportunities in the United Kingdom.
ERx Group / Acute Care: The company was acquired by Acute Care for an undisclosed amount on May 16, 2022. The company is a provider of healthcare services to communities in the United States.
Guardian Medical Monitoring / ModivCare: The company, a subsidiary of Guardian Alarm, was acquired by ModivCare for an undisclosed amount on May 18, 2022. The company is a manufacturer of remote patient monitoring products catering to managed care organizations, state Medicaid payors and aging and chronically ill patients.
Multi-Specialty Research Associates / Wake Research Associates: The company was acquired by Wake Research Associates, a subsidiary of M3 USA, for an undisclosed amount on May 18, 2022. The company is a provider of clinical trial services based in Lake City, Florida.
Novosteo / Cortexyme: The company was acquired by Cortexyme for an undisclosed amount on May 20, 2022. The company is a developer of a drug discovery platform designed to reduce the morbidity, mortality, and loss of productivity associated with bone fractures.
OpenHealth Company / AGIR à dom: The company was acquired by AGIR à dom for an undisclosed amount on May 19, 2022. The company is a provider of a healthcare data collection and analysis platform.
Osteogenics Biomedical / Envista Holdings: The company reached a definitive agreement to be acquired by Envista Holdings for an undisclosed amount on May 17, 2022. The company is a developer of dental bone grafting designed for regenerative and implant dentistry.
Sparo / Wellinks: The company was acquired by Wellinks (New Haven) for an undisclosed amount on May 17, 2022. The company is a digital healthcare business intended to develop devices to measure lung function for respiratory care.
Synergy Health / Steris: The company, a subsidiary of SYNLAB International, was acquired by Steris for an undisclosed amount on May 17, 2022. The company is a provider of outsourced sterilization services to the healthcare sector.